New York, New York-- (Newsfile Corp. - February 15, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

If you purchased or acquired securities in BioAge between September 26, 2024 and January 7, 2025 and would like to discuss ...

Methods Patients with RA in the Clinical Practice Research Datalink starting MTX between 1987 and 2016 were included. Hepatotoxicity was defined as transaminitis: alanine transaminase or aspartate ...

Third Harmonic Bio plans a Phase 2 trial for THB335 in chronic spontaneous urticaria and will reduce its workforce by 50% ...

Glucarpidase treatment significantly improves kidney recovery odds and reduces risks of neutropenia and transaminitis in MTX-AKI patients. The study utilized a target trial emulation framework to ...

The law firm of Kirby McInerney LLP reminds investors of the March 10, 2025, deadline to seek the role of lead plaintiff in a federal securities class action filed on behalf of investors who acquired ...

Third Harmonic Bio shares dived 35% in premarket trading amid a broader evaluation of THB335. Shares were trading around $3.03. The stock is down 50% over the last year.

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been ...

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against BioAge Labs, Inc. ("BioAge" or the "Company") ...

Apply for lead plaintiff in BioAge Labs securities class action by March 10, 2025. Contact Kirby McInerney LLP to learn your ...

The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action lawsuit has been ...

the potential for liver transaminitis in any of its previous clinical Phase 1 trials and various preclinical tox studies; (2) potential safety concerns with the Company's ongoing STRIDES clinical ...